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Background
Sex was the strongest determinant of subjective tolerabil-
ity of antipsychotic drugs in a recent study (Barbui et al.,
2005) and the authors suggested that studies should no
longer consider men and women as a homogenous group.
The aim of this review is to investigate whether sex differ-
ences exist for susceptibility to adverse effects of second-
generation antipsychotics (SGAs).
Materials and methods
Results are based on a Medline search for controlled trials
of all atypical antipsychotics.
Results
It is known that pharmacokinetics differ between females
and males, with a higher activity in females for CYP3A4
and CYP2D6. Yet, significantly higher plasma levels in
women have only been demonstrated for olanzapine and
clozapine. Regarding side effects, although not well stud-
ied, some of them such as hyperprolactinaemia, weight
gain and cardiac effects are reported to affect more often
women. There is -although controversial- evidence for
more pronounced prolactin levels in females. There are
also some published studies that indicate that metabolic
syndrome (visceral adiposity, hyperglycaemia, hyperten-
sion and dyslipidaemia) induced by SGAs is more fre-
quent in females. Lastly, the risk of QT prolongation is
again higher in females. There is no evidence for sex dif-
ferences in SGAs causing extrapyramidal symptoms, acute
dystonia or any other movement disturbance.
Conclusions
In conclusion, there is some evidence of sex differences in
side effects of the SGAs. However, data are obtained by
posthoc analysis, not to mention that clinical trials of new
therapeutic drugs have been conducted, for the most part,
with male participants. Future studies with a primary
focus on sex differences are required and will help to
determine how these differences should influence clinical
management.
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